Azitra Q1 net loss $3.9M; adds MD Anderson for ATR-04 trial

Azitra, Inc.

2026-Q1 EPS reported -$0.25

Net loss $3.9M ($1.6M R&D, $2.4M G&A); cash $10.1M at March 31, 2026.
Added MD Anderson Cancer Center as clinical site for Phase 1/2 trial of ATR-04 targeting EGFRi-associated rash.
Launched cosmeceutical initiative using filaggrin protein/peptide technologies for fine lines and wrinkles.
Secured new U.S. patent for ATR-12 (Netherton syndrome); Phase 1b topline data expected H2 2026.
Private placement financing of up to ~$10.5M (up to ~$20.9M if warrants exercised).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Azitra, Inc. reported the quarter ended March 31, 2026 results: net income $3.9 million.

Period: the quarter ended March 31, 2026
Net income: $3.9 million
Result: reported results

Exact text from the filing

Net Loss was $3.9 million for the quarter ended March 31, 2026, compared to $3.1 million for the comparable period in 2025.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Azitra, Inc. filing history →

Source: SEC EDGAR

accession 0001701478-26-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.